DAVID G JOHNSON to Thalidomide
This is a "connection" page, showing publications DAVID G JOHNSON has written about Thalidomide.
Connection Strength
1.103
-
Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017 10 05; 130(14):1639-1643.
Score: 0.475
-
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 01; 29(7):797-804.
Score: 0.301
-
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008 Dec 15; 112(13):4924-34.
Score: 0.256
-
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010 Jul 15; 116(2):250-3.
Score: 0.072